Andere talen Sana Biotechnology, Inc.

Aandelen

SANA

US7995661045

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 22-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
7,93 ^USD	+4,20%		-7,25%	+94,36%

18/04	Sana Biotechnology, Inc. kondigt aan dat Douglas Williams ontslag neemt als Executive Vice President en President, Onderzoek en Ontwikkeling	CI
01/03	SANA BIOTECHNOLOGY, INC. : JMP Securities ontvangt een koopadvies	ZM

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Sana Biotechnology, Inc. Announces Resignation of Douglas Williams as Executive Vice President and President, Research and Development	18/04
Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences	09/04
Certain Restricted Stock Units of Sana Biotechnology, Inc. are subject to a Lock-Up Agreement Ending on 9-APR-2024.	09/04
Certain Stock Options of Sana Biotechnology, Inc. are subject to a Lock-Up Agreement Ending on 9-APR-2024.	09/04
Certain Common Stock of Sana Biotechnology, Inc. are subject to a Lock-Up Agreement Ending on 9-APR-2024.	09/04
Sana Biotechnology Shares Rise as Q4 Non-GAAP Net Loss Narrows	01/03
Sector Update: Health Care Stocks Edge Higher Premarket Friday	01/03
Sana Biotechnology Q4 Non-GAAP Net Loss Narrows; Cash, Cash Equivalents Decline	29/02
Sana: Q4 Earnings Snapshot	29/02
Sana Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/02
Sana Biotechnology, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	29/02
Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates	29/02
Sana Biotechnology to Present at the Cowen 44th Annual Health Care Conference	28/02
Viridian Therapeutics Names Jennifer Tousignant as Chief Legal Officer	16/02
Sana Biotechnology Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in a Diabetic NHP	13/02
Sana Biotechnology Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in a Diabetic NHP	13/02
Sana Biotechnology, Inc. Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in Diabetic NHP	13/02
Breaking Ground in BioPharma: Spotlight Companies DYAI, INBS, SANA, IOVA, BLUE	13/02
Sana Biotechnology Insider Bought Shares Worth $9,999,996, According to a Recent SEC Filing	12/02
Sana Biotechnology Insider Bought Shares Worth $9,999,996, According to a Recent SEC Filing	12/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Sana Biotechnology, Inc.

Aandelen

SANA

US7995661045

Andere talen

Filters